OPKO and Entera to present data on oral obesity treatment at ENDO 2025

MIAMI/JERUSALEM - OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) announced Wednesday that new in vivo data for their investigational oral OPK-88006 tablet will be presented at the ENDO 2025 annual meeting in San Francisco from July 12-15. Entera Bio, currently valued at $89 million, has maintained a strong financial position with a current ratio of 13.07, according to InvestingPro data.

The companies are jointly developing a dual GLP-1/glucagon peptide as both a once-daily tablet and a weekly subcutaneous injection for obesity, metabolic and fibrotic disorders. The oral formulation combines OPKO’s oxyntomodulin analog with Entera’s N-Tab technology. InvestingPro analysis shows Entera Bio holds more cash than debt on its balance sheet, with analysts projecting sales growth for the current year.

"Our once-daily tablet may be simpler to titrate and offer tolerability benefits," said Miranda Toledano, Chief Executive Officer of Entera, according to the press release.

The companies plan to file an Investigational New Drug application with the FDA later this year for both the oral tablet and weekly injectable formulations. OPKO will independently develop the injectable version, while Phase 1 clinical studies for both formulations are being planned.

The presentation, titled "First-in-Class Oral Dual GLP-1/Glucagon Agonist for Patients with Obesity and Metabolic Disorders: In Vivo Pharmacokinetic and Pharmacodynamic Results," is scheduled for Sunday, July 13, 2025.

Oral peptide treatments remain uncommon in metabolic therapy. The companies’ development program aims to provide options for treating obesity and related conditions such as fatty liver disease and other metabolic disorders.

This article is based on a press release statement from the companies.

In other recent news, Entera Bio Ltd. announced positive results from a Phase 2 study of its oral osteoporosis treatment, EB613. The study involved 161 postmenopausal women and demonstrated significant improvements in bone mineral density compared to a placebo. The trial’s findings, presented at the 2025 World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, highlighted gains in various bone density metrics using advanced 3D-DXA technology. Entera Bio’s CEO, Miranda Toledano, emphasized the potential of EB613 as an oral alternative to injectable treatments for osteoporosis. The company is preparing for a Phase 3 trial to further assess the drug’s safety and efficacy. These developments reflect Entera Bio’s commitment to providing innovative treatment options for osteoporosis. The announcement comes as the company aims to address a significant treatment gap for postmenopausal women at high risk of fractures. Entera Bio’s proprietary N-Tab™ technology supports its pipeline of oral peptide programs, including EB613.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.